Microscopic colitis can go into remission, and for a meaningful minority of people it stays away for years or even permanently. But for most, the condition behaves as a chronic, relapsing disorder rather than something that simply resolves on its own and never returns. A population-based study tracking patients over several years found that roughly a quarter relapsed after initially getting better, and treatment data consistently show high recurrence rates once medications are stopped. The good news is that microscopic colitis responds well to treatment, doesn’t raise your colon cancer risk, and doesn’t shorten your life in any meaningful way once other health conditions are accounted for. The frustrating part is that “going away” and “staying away” turn out to be very different questions.
What Happens Without Treatment
Some people with microscopic colitis do experience spontaneous remission, meaning their diarrhea stops without any specific therapy. This is more common in the lymphocytic colitis subtype than in collagenous colitis. A long-term population-based cohort study found that about 28% of patients relapsed after an initial period of improvement, with the median time to relapse sitting at roughly four years after diagnosis. There was no significant difference in relapse rates between collagenous and lymphocytic colitis.1PubMed Central. Long-Term Natural History of Microscopic Colitis: A Population-Based Cohort That means the majority stayed in remission through follow-up, but a sizable chunk saw symptoms return years later, sometimes when they thought the problem was behind them.
Research into the histological changes over time adds nuance. Patients with collagenous colitis were less likely to see their biopsy findings shift compared to those with lymphocytic colitis, but when it came to complete histological resolution, there was no clear difference between the two subtypes.2PubMed Central. The natural history of histological changes in microscopic colitis In other words, the colon’s appearance under a microscope doesn’t always match how someone feels. You can have lingering microscopic inflammation without diarrhea, or normal-looking biopsies and still feel lousy. This disconnect matters because it means a symptom-free period doesn’t necessarily equal a disease-free colon.
When Medications Are the Trigger
One scenario where microscopic colitis genuinely can go away is when it’s being driven by a medication you’re taking. Several drug classes are strongly linked to the condition. A systematic review and meta-analysis found that proton pump inhibitors (the acid-blocking drugs like omeprazole) more than doubled the odds of developing microscopic colitis, and the association was similar for SSRIs, NSAIDs, and statins.3PubMed Central. Are Drugs Associated with Microscopic Colitis? A Systematic Review and Meta-Analysis A separate study found that using NSAIDs and PPIs together carried roughly a fivefold increase in risk, and that continuous use for four to twelve months raised the danger further.4PubMed. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors
If a suspect medication is identified and stopped, the colitis sometimes resolves completely. This is the clearest path to microscopic colitis truly “going away.” The catch is that many people take these drugs for real, ongoing medical reasons, so stopping them isn’t always simple. And drug withdrawal doesn’t work for everyone; some patients stop the offending medication and still have active disease. Still, any evaluation of microscopic colitis should include a careful look at your medication list, because removing the trigger can be curative in a way that other treatments are not.
Budesonide Works Well but Doesn’t Cure
Budesonide, a locally acting steroid, is the workhorse treatment for microscopic colitis and has proven effective at inducing remission in both collagenous and lymphocytic forms.5PubMed Central. Use of budesonide in the treatment of microscopic colitis Response rates in multicenter studies run around 88%, and the drug works similarly well regardless of whether you’re younger or older at diagnosis.6PubMed Central. Clinical Characteristics and Treatment Response in Microscopic Colitis Based on Age at Diagnosis: A Multicenter Retrospective Study
The problem is what happens after you stop taking it. In a population-based study, about 63% of patients who achieved remission with budesonide had a recurrence after discontinuing the drug, with a median time to relapse of roughly three months.7PubMed Central. Budesonide Maintenance in Microscopic Colitis: Clinical Outcomes and Safety Profile from a Population-Based Study A randomized trial of low-dose maintenance budesonide painted an even starker picture: about 61% of patients on maintenance stayed in remission at one year versus only about 17% on placebo, and after the study ended, over 80% of those who had been on budesonide relapsed once the drug was withdrawn.8Gut. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial
For many people, then, microscopic colitis is managed rather than cured. Long-term low-dose budesonide keeps symptoms at bay, and the data show that virtually everyone who stays on maintenance therapy responds well. Among 56 patients on long-term maintenance in one cohort, all achieved a response, with 98% reaching complete remission, and none relapsed while still on the drug.7PubMed Central. Budesonide Maintenance in Microscopic Colitis: Clinical Outcomes and Safety Profile from a Population-Based Study But nearly half relapsed again once maintenance was eventually stopped. The pattern resembles managing a chronic condition with ongoing treatment, not eradicating a disease.
Bile Acid Malabsorption and an Overlooked Overlap
A surprisingly large share of people with microscopic colitis also have bile acid malabsorption, a condition where the body fails to properly recycle bile acids, leading to watery diarrhea that looks a lot like a microscopic colitis flare. One study found bile acid malabsorption in about 43% of patients with microscopic colitis, with a higher rate in those who had the lymphocytic subtype (60%) compared to collagenous colitis (27%).9PubMed. Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea In patients who had both conditions, cholestyramine (a bile acid binder) induced remission in the vast majority.
This overlap matters because if bile acid malabsorption is contributing to your symptoms, treating it directly with a bile acid sequestrant can make a real difference. In one of the largest cohorts evaluating these drugs in microscopic colitis, about two-thirds of patients had at least a partial response.10PubMed. Bile Acid Sequestrants in Microscopic Colitis: Clinical Outcomes and Utility of Bile Acid Testing Interestingly, bile acid testing didn’t reliably predict who would respond and who wouldn’t, so some doctors try the treatment empirically regardless of test results.11Clinical Gastroenterology and Hepatology. Bile Acid Sequestrants in Microscopic Colitis: Clinical Outcomes and Utility of Bile Acid Testing For patients who aren’t fully responding to budesonide alone, addressing bile acid malabsorption can be the piece that gets them feeling genuinely well.
Smoking and Risk of a Harder Course
Smoking is one of the strongest modifiable risk factors for developing microscopic colitis in the first place, and it appears to make the disease course more difficult. A large prospective study of U.S. women found that current smokers had roughly two and a half times the risk of developing microscopic colitis compared to nonsmokers. The association was strongest for collagenous colitis, where current smokers faced nearly four times the risk.12PubMed Central. Smoking is Associated with an Increased Risk of Microscopic Colitis: Results From Two Large Prospective Cohort Studies of US Women The risk climbed with more pack-years and dropped after quitting, which is encouraging if you’re looking for something actionable.
Separate research found that current smoking was associated with an increased risk of collagenous colitis specifically, while past smoking raised the risk for microscopic colitis more broadly. Smokers with microscopic colitis were also more likely to have overlapping irritable bowel syndrome symptoms.13PubMed Central. Smoking- and alcohol habits in relation to the clinical picture of women with microscopic colitis compared to controls If you’re a smoker dealing with stubborn microscopic colitis, quitting won’t guarantee remission, but it removes one of the factors that may be keeping the disease active.
When Standard Treatments Fail
A small percentage of patients don’t respond adequately to budesonide, bile acid binders, or medication withdrawal. For these refractory cases, biologic drugs targeting tumor necrosis factor (TNF) have shown promise. In a single-center study of 18 patients who hadn’t responded to budesonide, half achieved remission by 12 weeks on anti-TNF therapy (adalimumab or infliximab), and another third had a partial response. A subset achieved lasting remission with just the induction course alone.14PubMed Central. Single-centre experience with anti-tumour necrosis factor treatment in budesonide-refractory microscopic colitis patients Another report focused specifically on adalimumab concluded it could achieve clinical remission and improve quality of life in patients who had failed both budesonide and methotrexate.15PubMed. Adalimumab in budesonide and methotrexate refractory collagenous colitis
Surgery remains a last resort and is becoming increasingly rare as medical options improve. The available procedures include diverting ileostomy and subtotal colectomy, but evidence is limited to individual case reports rather than controlled studies.16Clinical and Experimental Gastroenterology. Management of microscopic colitis: challenges and solutions The practical message is that truly refractory, life-disrupting microscopic colitis exists but is uncommon, and biologics have filled much of the gap that previously led to surgical consideration.
Residual Symptoms Even After Remission
One of the more frustrating realities of microscopic colitis is that achieving remission of the diarrhea doesn’t always mean feeling normal. A case-control study comparing microscopic colitis patients in clinical remission to matched controls found that abdominal pain, fatigue, joint pain, and muscle pain remained significantly more common in the colitis group. For example, 36% of collagenous colitis patients in remission reported abdominal pain compared to 21% of controls, and 54% still experienced fatigue versus 34% of controls.17PubMed. Long-term prognosis of clinical symptoms and health-related quality of life in microscopic colitis: a case-control study
These lingering symptoms may partly explain why some patients feel like the disease hasn’t truly gone away even when their stool frequency has normalized. Some of this overlap likely reflects shared mechanisms with autoimmune conditions or irritable bowel syndrome. Microscopic colitis is commonly misdiagnosed as diarrhea-predominant IBS, and the two can coexist, meaning that even after the colitis is controlled, IBS-type symptoms may persist.18PubMed. Microscopic Colitis: A Diagnostic Challenge in Patients with Irritable Bowel Syndrome If you’re in remission by every standard measure but still don’t feel right, this is worth discussing with your gastroenterologist.
The Celiac Disease Connection
Microscopic colitis clusters with other autoimmune conditions, and the strongest link is with celiac disease. A meta-analysis of 26 studies found that celiac disease was present in about 6% of people with microscopic colitis, and microscopic colitis was found in about 6% of celiac disease patients. The association was strong, with odds roughly eight times higher than in the general population.19PubMed Central. The association between microscopic colitis and celiac disease: a systematic review and meta-analysis
This link matters for the “does it go away” question in an interesting way. Research in a female population found that celiac disease was most common in patients with lymphocytic colitis and in those who had only a single episode of microscopic colitis, as opposed to refractory or recurrent disease.20PubMed Central. Microscopic colitis found together with celiac disease in a female population is associated with one episode of lymphocytic colitis One interpretation is that when an undiagnosed gluten sensitivity is driving the colonic inflammation, treating the celiac disease (via a strict gluten-free diet) may allow the microscopic colitis to resolve. If you’ve been diagnosed with microscopic colitis and haven’t been screened for celiac disease, it’s worth asking your doctor about it, especially if you have the lymphocytic subtype.
Cancer Risk and Life Expectancy
A common worry with any chronic bowel condition is whether it increases your risk of colon cancer. With microscopic colitis, the answer is reassuring. A meta-analysis found that colorectal cancer rates were actually lower in people with microscopic colitis compared to the general population.21Inflammatory Bowel Diseases. Microscopic Colitis Is Associated With a Reduced Risk of Colorectal Adenoma and Cancer: A Meta-Analysis A separate retrospective study found no increased risk of colon cancer or precancerous polyps compared to a control group undergoing colonoscopy for other reasons, and having multiple episodes of microscopic colitis didn’t change the picture.22PubMed Central. Cancer risk in microscopic colitis: a retrospective cohort study Unlike ulcerative colitis or Crohn’s disease, microscopic colitis does not appear to be a cancer risk factor.23Clinical Gastroenterology and Hepatology. Microscopic Colitis and Risk of Colon Adenomas: A Multicenter Retrospective Cohort Study
Mortality data tell a similar story once you adjust for the bigger picture. A large Swedish study initially found a slightly higher death rate among microscopic colitis patients, but when the analysis accounted for the burden of other health conditions these patients carried, the excess risk disappeared entirely.24PubMed. Mortality of Patients With Microscopic Colitis in Sweden A Danish nationwide study came to a parallel conclusion: a modest increase in all-cause mortality was largely explained by comorbidities and smoking-related diseases rather than the colitis itself. Patients with microscopic colitis actually had a decreased risk of dying from colorectal cancer.25PubMed. All-cause and cause-specific mortality in microscopic colitis: a Danish nationwide matched cohort study In practical terms, microscopic colitis doesn’t shorten your life. The comorbidities that often travel alongside it, especially smoking-related conditions, are where the real risk lies.
What Gut Microbiome Research Is Showing
An emerging area of research involves the gut microbiome. Studies consistently find that people with microscopic colitis have reduced bacterial diversity and an overrepresentation of pro-inflammatory species, including certain oral-associated bacteria that shouldn’t normally be abundant in the colon. At the same time, protective species tend to be depleted.26PubMed Central. Dysbiosis of Gut Microbiota in Microscopic Colitis: Diagnostic and Therapeutic Implications One study found that this lower diversity was particularly evident in the lower colon and persisted even after accounting for medication use.27Clinical and Translational Gastroenterology. Microbial Associations With Microscopic Colitis
Whether this dysbiosis is a cause of microscopic colitis, a consequence of the inflammation, or something maintained by medications like PPIs is still unclear. A systematic review concluded that while the microbiome appears altered in microscopic colitis, researchers haven’t yet agreed on which specific bacterial changes matter most or how they relate to the disease course.28PubMed Central. Microbiome Composition in Microscopic Colitis: A Systematic Review No microbiome-targeted therapy, probiotics included, has proven effective for microscopic colitis in rigorous trials. This is an area where the science is genuinely early-stage, but it may eventually help explain why some people achieve lasting remission and others don’t.